STOK
Price:
$12.57
Market Cap:
$665.80M
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery...[Read more]
Industry
Biotechnology
IPO Date
2019-06-19
Stock Exchange
NASDAQ
Ticker
STOK
According to Stoke Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.39. This represents a change of -2.80% compared to the average of -5.55 of the last 4 quarters.
The mean historical PE Ratio of Stoke Therapeutics, Inc. over the last ten years is -26.02. The current -5.39 PE Ratio has changed 1.97% with respect to the historical average. Over the past ten years (40 quarters), STOK's PE Ratio was at its highest in in the September 2023 quarter at -1.78. The PE Ratio was at its lowest in in the March 2018 quarter at -78.61.
Average
-26.02
Median
-17.84
Minimum
-58.82
Maximum
-2.21
Discovering the peaks and valleys of Stoke Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 129.66%
Maximum Annual PE Ratio = -2.21
Minimum Annual Increase = -74.61%
Minimum Annual PE Ratio = -58.82
Year | PE Ratio | Change |
---|---|---|
2023 | -2.21 | -42.68% |
2022 | -3.86 | -62.94% |
2021 | -10.40 | -74.61% |
2020 | -40.98 | 129.66% |
2019 | -17.84 | -62.84% |
2018 | -48.01 | -18.37% |
The current PE Ratio of Stoke Therapeutics, Inc. (STOK) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.49
5-year avg
-15.06
10-year avg
-26.02
Stoke Therapeutics, Inc.’s PE Ratio is less than Adaptimmune Therapeutics plc (-3.84), less than Homology Medicines, Inc. (-0.01), less than Black Diamond Therapeutics, Inc. (-1.82), greater than Harpoon Therapeutics, Inc. (-122.60), less than Relay Therapeutics, Inc. (-1.74), less than Pliant Therapeutics, Inc. (-4.30), greater than Arvinas, Inc. (-5.78), less than Passage Bio, Inc. (-0.64), less than Atreca, Inc. (-0.06), less than TCR2 Therapeutics Inc. (-0.38),
Company | PE Ratio | Market cap |
---|---|---|
-3.84 | $172.52M | |
-0.01 | $3.02M | |
-1.82 | $132.97M | |
-122.60 | $865.08M | |
-1.74 | $716.40M | |
-4.30 | $868.99M | |
-5.78 | $1.70B | |
-0.64 | $43.85M | |
-0.06 | $3.57M | |
-0.38 | $58.11M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Stoke Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Stoke Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Stoke Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Stoke Therapeutics, Inc. (STOK)?
What is the highest PE Ratio for Stoke Therapeutics, Inc. (STOK)?
What is the 3-year average PE Ratio for Stoke Therapeutics, Inc. (STOK)?
What is the 5-year average PE Ratio for Stoke Therapeutics, Inc. (STOK)?
How does the current PE Ratio for Stoke Therapeutics, Inc. (STOK) compare to its historical average?